The future leaves
signals in time.

Nature Biotechnology published an item on AI-guided optimization for thermostable mRNA vaccines. The available context provides no further details on the methods, study stage, or outcomes, so no results can be confirmed from this item alone.

A Nature Biotechnology headline reports that lipid nanoparticles optimized for large RNA cargo and tissue targeting enhance in vivo genome editing. No supporting context was supplied, so methods, models and specific results are not available.

A large health-record analysis found glucosamine use associated with a 25% higher likelihood of mild cognitive impairment progressing to dementia. Lab experiments suggest it may intensify an abnormal sugar-tagging process in the Alzheimer’s brain, but clinical trials are needed to determine actual harm.

According to the randomized SINGLE-AF trial, direct oral anticoagulants cut the risk of serious clinical events by 69% in atrial fibrillation patients with an intermediate risk of stroke. The reported benefit was driven mainly by fewer ischemic strokes, with no increase in major bleeding.

A single dose of an experimental CRISPR therapy lowered LDL cholesterol and triglycerides by about half in patients with difficult-to-treat lipid disorders, with reductions still present one year later. At the highest dose, LDL fell 52.5% and triglycerides fell 47.8%; the therapy remains experimental.

Scientists have mapped the genetics of cat cancer at an unprecedented scale and found surprising similarities with tumors in humans. They say the findings could help bring precision cancer treatments to cats and offer new clues about how human cancers develop and respond to drugs.

A new analysis reexamined all eight major randomized screening trials, accounting for differences in follow-up time, screening frequency, and screening after the trials ended. Its results were consistent with an overdiagnosis rate below 5%, rather than earlier estimates approaching 30% to 50%, suggesting mammography overdiagnosis may be far lower than some prior studies indicated.

A major analysis suggests Phelan-McDermid syndrome, a genetic disorder closely linked to autism, may affect about 1 in 7,300 people and more than 45,000 Americans. Researchers warn thousands of cases may remain hidden because genetic testing is often not performed, while targeted treatments move into clinical trials.

Researchers used CRISPR to remove CD33 from donor stem cells, potentially offering a way to attack aggressive blood cancers while protecting healthy cells needed after transplant. In a reported 30-patient trial, the edited cells successfully took hold and appeared to shield blood cells from a CD33-targeted treatment; this remains an early-stage trial result.

Scientists discovered a backup system that lets mammalian cells produce the essential amino acid cysteine even when once-considered-indispensable pathways are disabled. The same survival mechanism may help cancer cells resist treatment, raising the possibility that shutting it down could make tumors easier to kill — a possibility, not a proven therapy.

ScienceDaily published this update. Read the original source for full details, conditions and limitations.

ScienceDaily published this update. Read the original source for full details, conditions and limitations.

ScienceDaily published this update. Read the original source for full details, conditions and limitations.

Nature published this update. Read the original source for full details, conditions and limitations.

Nature published this update. Read the original source for full details, conditions and limitations.

Nature published this update. Read the original source for full details, conditions and limitations.

ScienceDaily published this update. Read the original source for full details, conditions and limitations.